Trading

CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds

Summary

CG Oncology reported successful results from its Phase 3 clinical trial evaluating cretostimogene grenadenorepvec for bladder cancer treatment. The company leadership described the positive data as a major corporate milestone, noting the therapy achieved a significant recurrence benefit during the pivotal study.

CG Oncology Inc. (NASDAQ:CGON) on Monday announced positive topline results from its Phase 3 PIVOT-006 trial, which Arthur Kuan, chairman, president, and CEO of CG Oncology, called a defining milestone for the company. Kuan stated that the data position cretostimogene grenadenorepvec as the first and only therapeutic candidate to show a significant recurrence benefit in a pivotal Phase 3 study…

Source: Read the full story at Top Stories Feed

Follow Tech & Money Press for daily watchlists and market news

XFacebookInstagramTikTokYouTube
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.
About UsContactPrivacy PolicyDisclaimer
Not financial advice. Curated headlines link to their original publishers.